Novo Nordisk (NVO) posts Q3 sales for its weight loss drug Wegovy, contrasting rival Eli Lilly's (LLY) quarterly miss for its obesity drug, Zepbound. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback